PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Navigating Three BCMA-Targeted Modalities and Their Optimal Sequencing in Myeloma

belantamab mafodotinidecabtagene vicleucelciltacabtagene autoleucelteclistamabelranatamabtalquetamabBCMACAR-Tbispecific antibodyantibody-drug conjugatemultiple myelomatreatment sequencingnarrative reviewOncology Pharmacy Oncology

Background Information

BCMA-targeted therapies revolutionize multiple myeloma care, balancing efficacy with unique toxicities.

BCMA-targeted therapies have transformed multiple myeloma treatment due to their specific targeting and improved patient outcomes. Cil-cel shows promising long-term remission, while BsAb therapies offer flexible options but risk T-cell exhaustion and ADCs face ocular toxicity challenges. Understanding therapy characteristics and sequencing is crucial to optimize patient outcomes and manage unique adverse effects effectively. BCMA-targeted therapies require strategic sequencing to maximize efficacy and manage distinct side effects.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mihara K, Miyama T

Citation: Mihara K, Miyama T Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma. International journal of hematology. 2026;124(1):31-37. doi:10.1007/s12185-025-04128-4

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.